Early molecular changes predict cancer cachexia in LKB1-deleted mouse models of NSCLC.
🗓️ 2025-07-01
📰 Publication: Clinical And Translational Medicine
Read MoreEarly molecular changes predict cancer cachexia in LKB1-deleted mouse models of NSCLC.neoplasms
Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia.
In cancer cachexia, the presence of a tumor triggers systemic metabolic disruption that leads to involuntary body weight loss and accelerated mortality in affected patients. Here, we conducted transcriptomic and epigenomic profiling of the liver in various weight-stable cancer and...
🗓️ 2025-07-18
📰 Publication: Cell
Read MoreFunctional liver genomics identifies hepatokines promoting wasting in cancer cachexia.B0092 tumor-bearing mice are a new model for the study of cachexia in head and neck cancer.
Introduction: Head and neck cancer (HNC) accounts for ~4% of all cancers but causes ~15,000 deaths annually in the U.S. Over 40% of HNC patients present with cachexia, a severe comorbidity associated with skeletal muscle defects, worsened treatment response, and...
🗓️ 2025-07-21
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreB0092 tumor-bearing mice are a new model for the study of cachexia in head and neck cancer.Thymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.
The discovery of immune checkpoints links autoimmunity and cancer, with thymus atrophy reportedly causing autoimmune multiorgan inflammation. The impact of cancer cachexia on thymic involution and its clinical significance remains unclear. This study aimed to investigate this effect and its...
🗓️ 2025-08-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.
In cancer cachexia, cytokine release by tumours causes weight loss, decreased therapeutic efficacy, and worsened prognosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and fibroblast inducible factor 14 (Fn14) are cancer cachexia-related proteins; however, their expression in oesophageal squamous...
🗓️ 2025-07-15
📰 Publication: British Journal Of Cancer
Read MoreHigh expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.The Combination of Fat Distribution and BMI Redefines Obesity: Result From NHANES.
Body mass index (BMI) has well-recognized limitations, particularly in the context of the 'obesity paradox', where higher BMI does not consistently evaluate adverse outcomes. These limitations underscore the need for alternative approaches. This study aimed to redefine obesity using anthropometric...
🗓️ 2025-08-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThe Combination of Fat Distribution and BMI Redefines Obesity: Result From NHANES.Bridging the tumor microenvironment: the pivotal role of cancer-associated fibroblasts in tumor cachexia development.
🗓️ 2025-07-14
📰 Publication: Molecular Cancer
Read MoreBridging the tumor microenvironment: the pivotal role of cancer-associated fibroblasts in tumor cachexia development.The role of body composition in the development of diabetes mellitus among childhood cancer survivors, and novel intervention strategies to mitigate diabetes risk.
The growing population of childhood cancer survivors (CCSs) experiences a large burden of comorbidities, including a markedly increased risk of diabetes mellitus. Among CCSs, prediabetes and diabetes are important risk factors for subsequent cardiovascular disease, which is a leading cause...
🗓️ 2025-07-15
📰 Publication: Cancer
Read MoreThe role of body composition in the development of diabetes mellitus among childhood cancer survivors, and novel intervention strategies to mitigate diabetes risk.GDF15: from biomarker to target in cancer cachexia.
Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor...
🗓️ 2025-07-09
📰 Publication: Trends In Cancer
Read MoreGDF15: from biomarker to target in cancer cachexia.Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.
Cancer cachexia is a multifaceted metabolic syndrome characterized by severe loss of skeletal muscle and adipose tissue, diminishing both quality of life and survival in cancer patients. Despite its prevalence, effective treatments for cancer cachexia remain limited. The JAK/STAT signaling...
🗓️ 2025-07-03
📰 Publication: Journal Of Advanced Research
Read MoreScutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.Vascular collapse leads to muscle wasting in cancer cachexia.
🗓️ 2025-06-27
📰 Publication: Nature Cancer
Read MoreVascular collapse leads to muscle wasting in cancer cachexia.Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.
Cachexia is a syndrome in patients with cancer that reduces life quality and prognosis, characterized by severe weight loss, muscle atrophy, and anorexia. How cachexia adversely affects older patients with small cell lung cancer (SCLC) remains uncertain. This study aimed...
🗓️ 2025-06-01
📰 Publication: Thoracic Cancer
Read MoreEffect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.Exercise and Nutrition Therapy in a Patient With Glottic Cancer Cachexia Undergoing Chemoradiotherapy: A Case Report.
Cancer cachexia is a common complication in patients undergoing chemoradiotherapy (CRT) for head and neck cancer (HNC), leading to skeletal muscle loss, decreased physical function, and poor prognosis. Cachexia is frequently observed in patients with HNC, yet evidence supporting effective...
🗓️ 2025-05-20
Read MoreExercise and Nutrition Therapy in a Patient With Glottic Cancer Cachexia Undergoing Chemoradiotherapy: A Case Report.Anti-CGRP Monoclonal Antibodies Counteract Establishment of Food Aversive Memories and Chemotherapy-induced Anorexia and Weight Loss.
Glutamatergic neurons of external lateral parabrachial nucleus co-expressing calcitonin gene related peptide (elPB CGRP) negatively regulate food intake and establish food aversive memories. They also promote malaise-dependent anorexia, sickness behavior and tumor cachexia. In spite of the pathogenetic potential of...
🗓️ 2025-06-07
📰 Publication: Pharmacological Research
Read MoreAnti-CGRP Monoclonal Antibodies Counteract Establishment of Food Aversive Memories and Chemotherapy-induced Anorexia and Weight Loss.Haptoglobin and Glutamine Synthetase May Biomark Cachexia Induced by Antiacute Myeloid Leukaemia Chemotherapy.
Anticancer chemotherapy is an underappreciated contributor to cancer cachexia, an often-irreversible body-wasting condition that causes 20%-30% of cancer-related deaths. An obstacle to predicting, monitoring and understanding the mechanisms underlying chemotherapy cachexia is that each cancer (and subtype) is assigned different...
🗓️ 2025-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreHaptoglobin and Glutamine Synthetase May Biomark Cachexia Induced by Antiacute Myeloid Leukaemia Chemotherapy.Comment on "Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review" by Dajani et al.
🗓️ 2025-01-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreComment on "Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review" by Dajani et al.